徐骋昊, 邬鹏程, 黄通敏, 陆海美, 许正浩. 耐药性癫痫发病机制及其治疗研究进展J. 药学学报, 2023, 58(3): 581-592. DOI: 10.16438/j.0513-4870.2022-1096
引用本文: 徐骋昊, 邬鹏程, 黄通敏, 陆海美, 许正浩. 耐药性癫痫发病机制及其治疗研究进展J. 药学学报, 2023, 58(3): 581-592. DOI: 10.16438/j.0513-4870.2022-1096
XU Cheng-hao, WU Peng-cheng, HUANG Tong-min, LU Hai-mei, XU Zheng-hao. Research progress on pathogenesis and treatment of drug-resistant epilepsyJ. Acta Pharmaceutica Sinica, 2023, 58(3): 581-592. DOI: 10.16438/j.0513-4870.2022-1096
Citation: XU Cheng-hao, WU Peng-cheng, HUANG Tong-min, LU Hai-mei, XU Zheng-hao. Research progress on pathogenesis and treatment of drug-resistant epilepsyJ. Acta Pharmaceutica Sinica, 2023, 58(3): 581-592. DOI: 10.16438/j.0513-4870.2022-1096

耐药性癫痫发病机制及其治疗研究进展

Research progress on pathogenesis and treatment of drug-resistant epilepsy

  • 摘要: 癫痫是一种慢性神经系统疾病, 影响着全球7 000多万人。尽管已有30多种抗癫痫药物(antiepileptic drugs, AEDs) 上市, 但仍有约1/3癫痫患者的癫痫发作无法被药物有效控制, 而成为耐药性癫痫患者。明确耐药性癫痫机制和开发有效的耐药性癫痫治疗方法已经成为癫痫研究领域的热点内容。本篇综述从中枢转运体、神经网络和药物靶点3个假说对耐药性癫痫发病机制研究进展进行探讨, 并对现有的切除手术、深部脑刺激、生酮饮食、精确治疗及中医药治疗等耐药性癫痫潜在治疗方法及其研究进展进行整理, 以期为耐药性癫痫的机制研究及临床治疗提供参考。

     

    Abstract: Epilepsy is a chronic nervous system disease, which affects more than 70 million people all over the world. Although more than 30 kinds of antiepileptic drugs (AEDs) have been on the market, about one third of the patients with epilepsy fail to respond to medical treatment, who become drug-resistant epilepsy patients. Identifying the mechanism and developing effective treatment methods for drug-resistant epilepsy have become a hot area in the field of epilepsy research. This review discussed resent advance on the pathogenesis of drug-resistant epilepsy from the transporter hypothesis, neural network hypothesis and target hypothesis, and we also summarized the existing potential treatment methods and research progress of drug-resistant epilepsy, such as surgical resection, deep brain stimulation, ketogenic diet, precise treatment, and traditional Chinese medicine treatment. Our review may provide useful clues for the mechanisms research and clinical treatments of drug-resistant epilepsy.

     

/

返回文章
返回